Imaxio - Product Pipeline Review - 2012 New Report


Naperville, IL -- (SBWIRE) -- 09/24/2012 -- Imaxio - Product Pipeline Review - 2012 provides data on the Imaxio’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.


- Imaxio - Brief Imaxio overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Imaxio human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Imaxio with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Imaxio’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Imaxio’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Imaxio in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Imaxio’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Imaxio.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Imaxio and identify potential opportunities in those areas.


Current R&D Portfolio of Imaxio; Imaxio - Key Therapeutics; Imaxio - Pipeline Overview and Promising Molecules; Imaxio - News; Imaxio - Latest Updates; Imaxio - Pipeline; Imaxio - Discontinued/Dormant Projects

To view table of contents for this market report please visit: